Scynexis pulls vaginal infection tablet from shelves, pauses ongoing trials on the heels of contamination risk concerns

Scynex­is is pulling its vagi­nal in­fec­tion drug Brex­afemme (ibrex­a­fungerp) from the mar­ket and plac­ing a tem­po­rary hold on on­go­ing clin­i­cal tri­als due to con­t­a­m­i­na­tion risk is­sues spot­ted by its prod­uct li­cen­sor GSK. Ibrex­a­fungerp will on­ly be made avail­able again once there is a mit­i­ga­tion strat­e­gy and re­sup­ply plan in place.

Scynex­is’ shares $SCYX were down 45% af­ter Mon­day’s stock mar­ket open­ing. GSK li­censed ibrex­a­fungerp from Scynex­is in March with an up­front pay­ment of $90 mil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.